Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patient

Journal of Clinical Psychiatry

Volumn 65, Issue 12, 2004, Pages 1723-1724

  Arnold, David S ^a   Rosse, Richard B ^a   Dickinson, Dwight ^a   Benham, Rhonda ^a   Deutsch, Stephen I ^a   Nelson, Matthew W ^b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; NICOTINIC RECEPTOR; PSYCHOTROPIC AGENT;

ADULT; CASE REPORT; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; EMOTIONAL DISORDER; HOSPITALIZATION; HUMAN; LETTER; MALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; AFFECTIVE SYMPTOMS; CHOLINESTERASE INHIBITORS; DRUG THERAPY, COMBINATION; GALANTAMINE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PSYCHOTROPIC DRUGS; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 13744263724     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n1219e     Document Type: Letter

References (9)

1. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000;157:4-15
2. Raskind MA, Peskind ER, Wessel T, et al, and the Galantamine USA-1 Study Group. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-2268
3. Tariot PN, Solomon PR, Morris JC, et al, and the Galantamine USA-10 Study Group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-2276
4. Adler LE, Olincy A, Waldo M, et al. Schizophrenia, sensory gating, and nicotine receptors. Schizophr Bull 1998;24:189-202
5. Breese CR, Lee MJ, Adams CE, et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000;23:351-364
6. Albuquerque EX, Alkondon M, Pereira EFR, et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997;280:1117-1136
7. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991;38:143-162
8. Leonard S, Gault J, Hopkins J, et al. Association of promoter variants in the α7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry 2002;59:1085-1096
9. Rosse RB, Deutsch SI. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol 2002;25:272-275